Patient characteristics
| Variables . | Older cohort (patient age ≥50 y) . | Younger cohort (patient age <50 y) . | ||||||
|---|---|---|---|---|---|---|---|---|
| CBT . | Younger haplo . | Older haplo . | P value . | CBT . | Younger haplo . | Older haplo . | P value . | |
| n = 2675 . | n = 451 . | n = 120 . | n = 1532 . | n = 171 . | n = 167 . | |||
| Age, y (range) | 61 (50-70) | 61 (50-70) | 59 (50-70) | .034 | 40 (16-49) | 34 (16-49) | 41 (16-49) | <.001 |
| Follow-up period, d (range) | 359 (0-2397) | 409 (8-2379) | 285 (3-1698) | .088 | 626 (0-2382) | 504 (7-2058) | 534 (7-2400) | .55 |
| HSCT y (%) | ||||||||
| 2016-2018 | 1266 (47.3) | 134 (29.7) | 30 (25.0) | <.001 | 735 (48.0) | 57 (33.3) | 66 (39.5) | <.001 |
| 2019-2021 | 1409 (52.7) | 317 (70.3) | 90 (75.0) | 797 (52.0) | 114 (66.7) | 101 (60.5) | ||
| Donor age, y (range) | 0 (0-0) | 30 (14- 39) | 48 (40- 65) | 0 (0-0) | 25 (13- 39) | 47 (40- 65) | ||
| Disease (%) | ||||||||
| AML | 1679 (62.8) | 241 (53.4) | 75 (62.5) | .001∗ | 914 (59.7) | 96 (56.1) | 85 (50.9) | .074∗ |
| ALL | 364 (13.6) | 70 (15.5) | 16 (13.3) | 428 (27.9) | 51 (29.8) | 61 (36.5) | ||
| MDS | 579 (21.6) | 135 (29.9) | 25 (20.8) | 141 (9.2) | 13 (7.6) | 18 (10.8) | ||
| CML | 53 (2.0) | 5 (1.1) | 4 (3.3) | 49 (3.2) | 11 (6.4) | 3 (1.8) | ||
| Disease risk (%) | ||||||||
| Low risk | 1296 (48.7) | 235 (53.0) | 72 (60.0) | .017 | 980 (64.1) | 116 (68.2) | 123 (74.1) | .026 |
| High risk | 1365 (51.3) | 208 (47.0) | 48 (40.0) | 549 (35.9) | 54 (31.8) | 43 (25.9) | ||
| HCT-CI (%) | ||||||||
| 1,2 | 2035 (76.5) | 346 (76.7) | 95 (79.8) | .703 | 1335 (87.7) | 152 (89.4) | 140 (84.8) | .435 |
| >2 | 625 (23.5) | 105 (23.3) | 24 (20.2) | 188 (12.3) | 18 (10.6) | 25 (15.2) | ||
| Performance status (%) | ||||||||
| 0-1 | 2424 (90.8) | 408 (90.5) | 110 (92.4) | .8 | 1430 (93.5) | 163 (95.3) | 157 (94.0) | .628 |
| 2-4 | 247 (9.2) | 43 (9.5) | 9 (7.6) | 100 (6.5) | 8 (4.7) | 10 (6.0) | ||
| Conditioning regimen (%) | ||||||||
| MAC | 1492 (55.8) | 146 (32.4) | 43 (35.8) | <.001 | 1335 (87.1) | 138 (80.7) | 133 (79.6) | .004 |
| RIC | 1183 (44.2) | 305 (67.6) | 77 (64.2) | 197 (12.9) | 33 (19.3) | 34 (20.4) | ||
| Sex mismatch (%) | ||||||||
| Others | 1864 (69.9) | 349 (77.4) | 78 (65.0) | .002 | 1145 (74.8) | 129 (75.4) | 108 (68.7) | .016 |
| Female to male | 803 (30.1) | 102 (22.6) | 42 (35.0) | 385 (25.2) | 42 (24.6) | 59 (35.3) | ||
| Source (%) | ||||||||
| CB | 2675 (100.0) | 0 (0.0) | 0 (0.0) | 1532 (100.0) | 0 (0.0) | 0 (0.0) | ||
| PBSC | 0 (0.0) | 451 (100) | 120 (00) | 0 (0.0) | 171 (100) | 167 (100) | ||
| Cytomegalovirus serostatus (%) | ||||||||
| (+) | 2286 (85.5) | 401 (88.9) | 105 (87.5) | .244 | 1165 (76.1) | 125 (73.1) | 134 (80.2) | .646 |
| (−) | 311 (11.6) | 36 (8.0) | 12 (10.0) | 337 (22.0) | 42 (24.6) | 30 (18.0) | ||
| Not reported | 78 (2.9) | 14 (3.1) | 3 (2.5) | 29 (1.9) | 4 (2.3) | 3 (1.8) | ||
| Variables . | Older cohort (patient age ≥50 y) . | Younger cohort (patient age <50 y) . | ||||||
|---|---|---|---|---|---|---|---|---|
| CBT . | Younger haplo . | Older haplo . | P value . | CBT . | Younger haplo . | Older haplo . | P value . | |
| n = 2675 . | n = 451 . | n = 120 . | n = 1532 . | n = 171 . | n = 167 . | |||
| Age, y (range) | 61 (50-70) | 61 (50-70) | 59 (50-70) | .034 | 40 (16-49) | 34 (16-49) | 41 (16-49) | <.001 |
| Follow-up period, d (range) | 359 (0-2397) | 409 (8-2379) | 285 (3-1698) | .088 | 626 (0-2382) | 504 (7-2058) | 534 (7-2400) | .55 |
| HSCT y (%) | ||||||||
| 2016-2018 | 1266 (47.3) | 134 (29.7) | 30 (25.0) | <.001 | 735 (48.0) | 57 (33.3) | 66 (39.5) | <.001 |
| 2019-2021 | 1409 (52.7) | 317 (70.3) | 90 (75.0) | 797 (52.0) | 114 (66.7) | 101 (60.5) | ||
| Donor age, y (range) | 0 (0-0) | 30 (14- 39) | 48 (40- 65) | 0 (0-0) | 25 (13- 39) | 47 (40- 65) | ||
| Disease (%) | ||||||||
| AML | 1679 (62.8) | 241 (53.4) | 75 (62.5) | .001∗ | 914 (59.7) | 96 (56.1) | 85 (50.9) | .074∗ |
| ALL | 364 (13.6) | 70 (15.5) | 16 (13.3) | 428 (27.9) | 51 (29.8) | 61 (36.5) | ||
| MDS | 579 (21.6) | 135 (29.9) | 25 (20.8) | 141 (9.2) | 13 (7.6) | 18 (10.8) | ||
| CML | 53 (2.0) | 5 (1.1) | 4 (3.3) | 49 (3.2) | 11 (6.4) | 3 (1.8) | ||
| Disease risk (%) | ||||||||
| Low risk | 1296 (48.7) | 235 (53.0) | 72 (60.0) | .017 | 980 (64.1) | 116 (68.2) | 123 (74.1) | .026 |
| High risk | 1365 (51.3) | 208 (47.0) | 48 (40.0) | 549 (35.9) | 54 (31.8) | 43 (25.9) | ||
| HCT-CI (%) | ||||||||
| 1,2 | 2035 (76.5) | 346 (76.7) | 95 (79.8) | .703 | 1335 (87.7) | 152 (89.4) | 140 (84.8) | .435 |
| >2 | 625 (23.5) | 105 (23.3) | 24 (20.2) | 188 (12.3) | 18 (10.6) | 25 (15.2) | ||
| Performance status (%) | ||||||||
| 0-1 | 2424 (90.8) | 408 (90.5) | 110 (92.4) | .8 | 1430 (93.5) | 163 (95.3) | 157 (94.0) | .628 |
| 2-4 | 247 (9.2) | 43 (9.5) | 9 (7.6) | 100 (6.5) | 8 (4.7) | 10 (6.0) | ||
| Conditioning regimen (%) | ||||||||
| MAC | 1492 (55.8) | 146 (32.4) | 43 (35.8) | <.001 | 1335 (87.1) | 138 (80.7) | 133 (79.6) | .004 |
| RIC | 1183 (44.2) | 305 (67.6) | 77 (64.2) | 197 (12.9) | 33 (19.3) | 34 (20.4) | ||
| Sex mismatch (%) | ||||||||
| Others | 1864 (69.9) | 349 (77.4) | 78 (65.0) | .002 | 1145 (74.8) | 129 (75.4) | 108 (68.7) | .016 |
| Female to male | 803 (30.1) | 102 (22.6) | 42 (35.0) | 385 (25.2) | 42 (24.6) | 59 (35.3) | ||
| Source (%) | ||||||||
| CB | 2675 (100.0) | 0 (0.0) | 0 (0.0) | 1532 (100.0) | 0 (0.0) | 0 (0.0) | ||
| PBSC | 0 (0.0) | 451 (100) | 120 (00) | 0 (0.0) | 171 (100) | 167 (100) | ||
| Cytomegalovirus serostatus (%) | ||||||||
| (+) | 2286 (85.5) | 401 (88.9) | 105 (87.5) | .244 | 1165 (76.1) | 125 (73.1) | 134 (80.2) | .646 |
| (−) | 311 (11.6) | 36 (8.0) | 12 (10.0) | 337 (22.0) | 42 (24.6) | 30 (18.0) | ||
| Not reported | 78 (2.9) | 14 (3.1) | 3 (2.5) | 29 (1.9) | 4 (2.3) | 3 (1.8) | ||
ALL, acute lymphoblastic leukemia; BM, bone marrow; HCT-CI, HCT-specific comorbidity index; PBSC, peripheral stem cell.
AML vs others.